Synthetic Pharmaceutical (832077) company declared the chemical drug 1.1 new drug "Levornidazole phosphate disodium and Levornidazole phosphate disodium for injection", obtained the drug clinical trial approval issued by the State Food and Drug Administration, approved the product for clinical trials.

Ornidazole is a commonly used anti-anaerobic drug at present. As the third generation anti-anaerobic infection drug after metronidazole and tinidazole, its efficacy is positive and side effects are small, and it has been widely recognized in clinical practice.
      Levornidazole disodium phosphate is a new compound formed by chemical structure modification of Levornidazole (patent license number of Levornidazole phosphate disodium phosphate compounds: ZL200610166893.2, ZL200710188487.0). Pharmacokinetic studies show that Levornidazole disodium phosphate can be rapidly decomposed into levornidazole in vivo.